Go back to Resources

Development of cerebral lateralization in children exposed to fetal antiseizure medications: A prospective cohort study at age 6 years

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Go back to Resources

Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Go back to Resources

Interaction of identity and beliefs with genetic literacy

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Go back to Resources

Mental health challenges associated with sickle cell disease and strategies to address them: Reflections from a community input panel

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Go back to Newsroom

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia

Go back to Newsroom

Go back to Resources

The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Go back to Resources

Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease

Authors:

Volume:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Go back to Newsroom

Emmes Appoints Matt Bond as CFO

Reportedly, Matt Bond’s expertise in mergers and acquisitions (M&A) and his track record with successful private-equity-backed enterprises are expected to be valuable assets in Emmes’ growth and diversification strategy.

US-based Clinical Research Organisation (CRO) Emmes has named Matt Bond as its Chief Financial Officer (CFO), succeeding former CFO Brian Hochheimer.

Go back to Newsroom

Go back to Newsroom

US-Based Emmes Acquires VaxTRIALS

This strategic acquisition is part of Emmes’ broader objective to expand its global presence beyond its existing operations in North America, Europe, and Asia into the Latin American market. The move is expected to strengthen Emmes’ expertise in one of its core research focus areas: vaccines and infectious diseases.

US-based Clinical Research Organisation (CRO) Emmes has acquired VaxTRIALS, a specialised Clinical Research Organisation headquartered in Panama City.

Go back to Newsroom

Go back to Newsroom

Emmes announces reorganization and launch of AI unit

Go back to Newsroom